Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AMRN with free AI briefings, catalyst countdowns, and dilution alerts.

AMRN · AMARIN CORP PLC\UK

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$323.4M Cash on Hand
CF+ Cash Runway
Follow AMRN by email Get an email when AMRN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AMRN, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Icosapent Ethyl (AMR101)
FDA approved Jul 2012 · Vascepa
Covid19 Phase 4 · NCT04505098 Terminated
Ethyl-EPA (Miraxion™) Huntington Disease Phase 3 · NCT00146211 Completed
HMG-CoA Reductase Inhibitor Cardiovascular Diseases Phase 3 · NCT01492361 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AMRN holds $323.4M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AMRN files for a raise →

👥 Who Owns AMRN

Insiders 100% Institutions (100 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Sarissa Capital Management LP 5%+ holder (13D) 25,743,900 6,762.36% 2026-08-25
Michael Torok
Director
Insider 4,850,000 1,273.99% 2025-04-03
Aaron Berg
President and CEO · +164,316 options
Insider 85,648 22.50% 2026-06-26
Steven B Ketchum
EVP, Chief Scientific Officer · +36,060 options
Insider 42,680 11.21% 2026-07-01
David Paul Keenan
EVP, Chief Operating Officer · +30,060 options
Insider 13,470 3.54% 2026-07-01
Peter L. Fishman
SVP, CFO · +468,225 options
Insider 7,619 2.00% 2026-08-01
Jonathan Provoost
EVP, Chief Legal Officer · +36,060 options
Insider 4,624 1.21% 2026-07-01
Louis III Sterling
Director · +838 options
Insider 4,049 1.06% 2026-04-18
Patrice Eadon Bonfiglio
Director · +838 options
Insider 836 0.22% 2026-04-18
Paul Cohen
Director · +838 options
Insider 836 0.22% 2026-04-18
Diane E. Sullivan
Director · +838 options
Insider 836 0.22% 2026-04-18
Keith Horn
Director · +838 options
Insider 836 0.22% 2026-04-18

Share count 380,694 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AMRN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AMRN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.